BMSN was absolutely a P D when it ran up to .014.
Post# of 5066
My point in my post had nothing to do in comparing what VICL and BMSN drug/therapy wise. It was only to point out that while science might look great on paper, it doesn't always pan out in clinical trials. BMSN's approach is quite unique by that it's using a patient's own cells and that's a good thing. I truly hope the FDA comes through and allows BMSN to go to trials with Hemaxellerate. I would like to actually make money off of BMSN than have to reply to your polyannish posts about BMSN.